Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1992 1
1993 1
1994 1
1997 1
2002 1
2006 1
2009 1
2010 1
2012 1
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Impaired thrombin-induced platelet aggregation"
Page 1
Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment.
Watanabe M, Siddiqui FM, Qureshi AI. Watanabe M, et al. Neurocrit Care. 2012 Feb;16(1):203-9. doi: 10.1007/s12028-011-9591-y. Neurocrit Care. 2012. PMID: 21748501 Review.
Dabigatran is a rapidly acting, and highly selective and reversible inhibitor of thrombin. It also has a potent inhibitory effect on thrombin-induced platelet aggregation, making it effective in preventing both venous and arterial thrombosis. ...Dabiga …
Dabigatran is a rapidly acting, and highly selective and reversible inhibitor of thrombin. It also has a potent inhibitory effect on thro …
Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors.
Coccheri S. Coccheri S. Drugs. 2010 May 7;70(7):887-908. doi: 10.2165/11536000-000000000-00000. Drugs. 2010. PMID: 20426498 Review.
Variability of response and 'resistance' may result from drug interactions, baseline and residual platelet hyperactivity, increased platelet turnover, pharmacogenetic factors and others. ...Among new adenosine diphosphate receptor antagonists, prasugrel is already r …
Variability of response and 'resistance' may result from drug interactions, baseline and residual platelet hyperactivity, increased …
Changes in platelet Bax levels contribute to impaired platelet response to thrombin after cardiopulmonary bypass: prospective observational clinical and laboratory investigations.
Murase M, Nakayama Y, Sessler DI, Mukai N, Ogawa S, Nakajima Y. Murase M, et al. Br J Anaesth. 2017 Dec 1;119(6):1118-1126. doi: 10.1093/bja/aex349. Br J Anaesth. 2017. PMID: 29040496 Free article.
METHODS: We assessed blood samples obtained from subjects having on-pump or off-pump coronary artery bypass graft surgery ( n =20 each). We also evaluated the in vitro effects of platelet Bax increase in eight healthy volunteers. RESULTS: Thrombin-induced …
METHODS: We assessed blood samples obtained from subjects having on-pump or off-pump coronary artery bypass graft surgery ( n =20 each). We …
Magnesium deficiency in alcoholism: possible contribution to osteoporosis and cardiovascular disease in alcoholics.
Abbott L, Nadler J, Rude RK. Abbott L, et al. Alcohol Clin Exp Res. 1994 Oct;18(5):1076-82. doi: 10.1111/j.1530-0277.1994.tb00084.x. Alcohol Clin Exp Res. 1994. PMID: 7847587 Review.
In these studies, Mg was shown to inhibit platelet aggregation against various aggregation agents. Patients with Mg deficiency were shown to have increased platelet aggregation that was normalized with Mg therapy. The antiplatelet effect of Mg m …
In these studies, Mg was shown to inhibit platelet aggregation against various aggregation agents. Patients with Mg def …
No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance.
Malmström RE, Settergren M, Böhm F, Pernow J, Hjemdahl P. Malmström RE, et al. Thromb Haemost. 2009 Jan;101(1):157-64. Thromb Haemost. 2009. PMID: 19132203 Clinical Trial.
Neither treatment affected basal or adenosine diphosphate (ADP)- or thrombin-induced platelet P-selectin expression, or fibrinogen binding, or platelet-leukocyte aggregation. Similarly, neither treatment affected ADP-induced platelet a …
Neither treatment affected basal or adenosine diphosphate (ADP)- or thrombin-induced platelet P-selectin expression, or …
Intracellular Ca2+ homeostasis and aggregation in platelets are impaired by ethanol through the generation of H2O2 and oxidation of sulphydryl groups.
Rosado JA, Nuñez AM, Lopez JJ, Pariente JA, Salido GM. Rosado JA, et al. Arch Biochem Biophys. 2006 Aug 1;452(1):9-16. doi: 10.1016/j.abb.2006.05.011. Epub 2006 Jun 16. Arch Biochem Biophys. 2006. PMID: 16824477
Ethanol (50 mM) induced H2O2 production in platelets by Ca2+-dependent and independent mechanisms. Ca2+ entry induced by ethanol was impaired by catalase. Ethanol reduced SOCE mediated by depletion of the 2,5-di-(tert-butyl)-1,4-hydroquinone (TBHQ)-sensitive acidic stores …
Ethanol (50 mM) induced H2O2 production in platelets by Ca2+-dependent and independent mechanisms. Ca2+ entry induced by ethanol was impa …
Defective calcium signalling in uraemic platelets and its amelioration with long-term erythropoietin therapy.
Zhou XJ, Vaziri ND. Zhou XJ, et al. Nephrol Dial Transplant. 2002 Jun;17(6):992-7. doi: 10.1093/ndt/17.6.992. Nephrol Dial Transplant. 2002. PMID: 12032187
BACKGROUND: Chronic renal failure (CRF) is associated with prolonged bleeding time and impaired platelet adhesion and aggregation. Erythropoietin (Epo) administration improves platelet adhesion/aggregation and ameliorates prolongation of bleedin …
BACKGROUND: Chronic renal failure (CRF) is associated with prolonged bleeding time and impaired platelet adhesion and aggre …
Platelet secretion defect associated with impaired liberation of arachidonic acid and normal myosin light chain phosphorylation.
Rao AK, Koike K, Willis J, Daniel JL, Beckett C, Hassel B, Day HJ, Smith JB, Holmsen H. Rao AK, et al. Blood. 1984 Oct;64(4):914-21. Blood. 1984. PMID: 6089937 Free article.
We describe four patients with impaired platelet aggregation and 14C-serotonin secretion during stimulation with adenosine diphosphate (ADP), epinephrine, collagen, and platelet-activating factor. ...Studies with 3H-arachidonic acid-labeled platelets r …
We describe four patients with impaired platelet aggregation and 14C-serotonin secretion during stimulation with adenos …
Neutrophils and mononuclear cells from patients with chronic granulomatous disease release nitric oxide.
Condino-Neto A, Muscará MN, Grumach AS, Carneiro-Sampaio MM, De Nucci G. Condino-Neto A, et al. Br J Clin Pharmacol. 1993 May;35(5):485-90. doi: 10.1111/j.1365-2125.1993.tb04174.x. Br J Clin Pharmacol. 1993. PMID: 8390277 Free PMC article.
Chronic granulomatous disease (CGD) is a group of genetic disorders characterised by recurrent severe suppurative infections due to impaired microbial killing. The principal biochemical defect is an impairment in the production of reactive oxygen intermediates by ph …
Chronic granulomatous disease (CGD) is a group of genetic disorders characterised by recurrent severe suppurative infections due to impai …
Platelets from patients on haemodialysis show impaired responses to nitric oxide.
Gordge MP, Neild GH. Gordge MP, et al. Clin Sci (Lond). 1992 Sep;83(3):313-8. doi: 10.1042/cs0830313. Clin Sci (Lond). 1992. PMID: 1327648
Platelets from patients on haemodialysis showed a loss of sensitivity to nitric oxide, reflected by a reduction in the ability of nitric oxide both to inhibit thrombin-induced aggregation and to increase intraplatelet cyclic GMP levels. Responses of platelets …
Platelets from patients on haemodialysis showed a loss of sensitivity to nitric oxide, reflected by a reduction in the ability of nitric oxi …
11 results